Category: Immunocompromised
Astrazeneca chief: Booster jabs for all are a waste of taxpayers cash
Widespread annual Covid-19 booster jabs are “not a good use” of taxpayer cash, according to the chief executive of AstraZeneca. More...
Preprint: An ongoing covid-19 infection lasting 471 days with THREE different variants
A truly extraordinary tale of a single patient with a 471 day ongoing Covid-19 infection involving three genetically distinct SARS-CoV-2 genotypes. More...
WHO: “Several children already infected” with Monkeypox
Just two days after deciding that the international Monkeypox outbreak wasn’t sufficiently serious enough to warrant designating it a Public Health Emergency of International Concern, the WHO are already backtracking. More...
Monkeypox: Nine dead in Congo, Nigeria sees 1st death from disease in 2022
Nine people have died of monkeypox in the Democratic Republic of the Congo in 2022 while Nigeria has recorded its first death from the disease this year. More...
Lancet: Where is the next SARS-CoV-2 variant of concern?
“Curing COVID-19 infections in immunocompromised individuals is of crucial importance.”… More...
Spillover of new BA.1 sublineage from persistently infected COVID patient into the community
“The new BA.1 sub-lineage transmitted to five independent cases, including two reported in GISAID from a different surveillance effort”…
Gisaid: BA.1 sublineage with T6001C and S mutations: S:E96D, S:L167T, S:R346T, S:L455W, S:K458M, S:E484V, S:H681R, S:P688V, detected in New York, USA #663. More...
Shielding “would not have been a viable public health strategy for COVID-19”
Shielding the vulnerable while allowing infections to spread among the wider population would not have been a viable public health strategy for COVID-19 and is unlikely to be effective for future pandemics. More...
France: Persistent Alpha variant infection in immunosuppressed patient in 2022
“We describe persistent circulation of SARS-CoV-2 Alpha variant in an immunosuppressed patient in France during February 2022. More...
Preprint: residual SARS-CoV-2 found in human tissue after 426 days
“We believe this study is the first to detect viral RNA and/or antigen in the tissues of patients with Long Covid, up to 426 days after the onset of COVID-19 symptoms.” More...
Paxlovid: Covid-19 infections rebounding a few days after treatment *4 UPDATES*
There are some anecdotal reports on social media today about Covid-19 infections rebounding a few days after taking Paxlovid. More...